Background: Multidrug-resistant tuberculosis (MDR-TB) demands diagnostics that combine rapid Mycobacterium tuberculosis(Mtb) detection with resistance genotyping. Objective: This narrative review synthesizes published evidence on CRISPR-Cas-basedplatforms (Cas12a, Cas12b, Cas13a, Cas14a) for Mtb detection and rpoB/katG/inhA resistance-mutation genotyping, benchmarkedagainst Xpert MTB/RIF(Ultra) and line-probe assays. Methods: Peer-reviewed primary studies, systematic reviews, andmeta-analyses reporting analytical or clinical performance of CRISPR-based TB assays were identified and synthesized narratively.Findings: Across assays, pooled CRISPR-based Mtb detection sensitivity and specificity reached 93% and 97%, respectively, withdrug-resistance genotyping sensitivity and specificity of 96% and 100%; a recent point-of-care sputum assay reported 100%sensitivity and specificity against culture, with limits of detection near 69-81 CFU/mL, comparable to Xpert Ultra. Conclusions:CRISPR-Cas diagnostics can match nucleic-acid-amplification-test accuracy for Mtb detection and resistance genotyping usingsimpler isothermal chemistry, though larger multicenter validation, guide-RNA panel standardization, and reagent-stabilitystudies are needed before widespread programmatic adoption.